Please complete your preliminary application, outlining the planned approach and adding supportive data, including your costing sheets. Please use this template to outline your costs and upload it to this form, along with this document to which you need to add your signed confirmation. 

  • Section 1: Research overview

  • MM slash DD slash YYYY

  • Section 1.1: Applicant details

  • Principal Investigator

  • Co-investigator

  • Project manager (if applicable)

  • Other collaborator (e.g. commercial / charity / CRO

  • Section 2: Medical need and proposed solution

  • Please present the disease that is the subject of the application include age of onset, mortality, morbidity, demographic etc. What is the disease health, clinical or product need you are seeking to address? Describe which organ(s) are to be targeted.
  • Please provide a summary including the following: Indication (disease targeted for the product), Biological activity (hypothesised biological function(s), Efficacy (proposed efficacy endpoints), Safety (potential safety risks associated with the product), Dosage form and Dosing, Route of Administration (proposed route of delivery for the product). TPP should capture key goals regarding clinical indication and target product quality characteristics.
  • What are the competing solutions in development and their shortcomings?
  • Please explain the scientific rationale for your proposed intervention, include data and experimental supporting evidence. This should include all pre-clinical data in models and toxicology data.
  • Describe the target gene providing as much detail as possible on structure and gene / part of the gene to be replaced or modified.
  • Provide a description of the proposed construct and vector. This should include the source of any material and ownership. If possible, any IP liabilities associated with the construct, including the vector, should be disclosed.
  • Explain the experimental design and provide a statistical justification. Specifically, animal numbers must be justified.
  • Explain the clinical trial design and provide a statistical justification. Specifically, participant numbers and access must be justified. Include proposed study design and delivery, proposed end-points, and potential safety risks and mitigations.
  • If yes, please detail your planned or predicted dose requirements (if known)
  • Do you produce R&D or GMP-grade viral vectors in-house or source them from elsewhere?
  • If produced in your lab / institution, please provide details of the process you currently use for making viral vectors including producer cell type, culture type (e.g. suspension or adherent), media and any other relevant factors.
  • If purchased elsewhere, please provide full details including the supplier’s name. We recognise there may confidentiality considerations for this question, please provide as much detail as possible.

  • Section 4: Intellectual Property

    Note that the generation of protectable intellectual property is not an essential requirement for this scheme however it is important to demonstrate that there is a credible route to the patient and that will not be impeded by the IP situation.
  • If access is required, what IP does the proposal need access to? Detail institutions or individuals holding relevant background IP.
  • If not, why do you believe you will be able to access the required IP on reasonable terms?
  • Detail the organisations/individuals who will own any arising IP and any live, pending or envisioned agreements governing management or exploitation of that IP
  • How is the project going to be supported after the end of the project? List potential sources of further funding and comment upon the project’s compatibility with the individual fund’s defined remits.

  • Section 5: Exploitation of the project's deliverables

  • How is the project going to be supported after the end of the project? List potential sources of further funding and comment upon the project’s compatibility with the individual fund’s defined remits.
  • Outline the likely route to market/patient benefit. If licensing anticipated, list potential partners and describe the required data package to be offered for licensing?

  • Section 6: Ethics

  • Section 7: Miscellaneous

  • Give details of previous awards that have supported the project (funder, grant title, amount awarded, grant period).
  • Please note any other issues not mentioned elsewhere in the application form.

  • Section 8: Financial support and resources requested

  • Please add your confirmations to the document which should contain your signatures, which you can download from the top of this page.
    Max. file size: 8 MB.
  • Use the the template to outline your costs from the top of this page as the basis, and expand as necessary.
    Max. file size: 8 MB.

  • Section 9: Declaration

  • Please select to confirm
  • Your application is subject to the Applicants Terms of Service (“Terms”). The Terms will apply when you click the submit button below. Please review the Terms carefully. By clicking submit, you confirm that you have read and accept the Terms and that you are authorised to do so.

    If you would like your data to be removed, please email dataprivacy@lifearc.org

    Please see our Privacy Policy in relation to the personal data you submit to us through this page.